Login
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

cellectar.com

What Do They Do?

Develops cancer drugs designed to carry radiation directly to cancer cells, for potential treatment of blood cancers and solid tumors in adults and children.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −79% (Loss)
vs −$4.4M in Q3 FY2025

Pipeline emphasis The older report described iopofosine as the lead, alongside a preclinical chemotherapy program, an alpha-emitter series and partnered assets. The latest report centers its pipeline on radioconjugates, including iopofosine and additional lead programs.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support